Early Intervention in Infants With Cerebral Palsy (CONTRACT)

November 1, 2022 updated by: Maria Willerslev-Olsen, University of Copenhagen

Protocol of a Two-group Open-label Randomized Clinical Trial With Blinded Assessment for Prevention of Contractures in Infants With High Risk of Cerebral Palsy.

Contractures are a frequent cause of reduced mobility in children with Cerebral palsy (CP) already at the age of 2-3 years. Reduced muscle use and muscle growth have been suggested as key factors in the development of contractures, suggesting that efficient early prevention will have to involve stimuli that can facilitate muscle growth already before the age of 1 year. The present study protocol was developed to assess the effectiveness of an early intervention program, CONTRACT, on muscle growth and mobility in children at very high risk of CP compared with best standard care.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Cerebral palsy (CP) is the most common cause of motor and cognitive disabilities in childhood affecting around 1 out of 500 newborn infants. Contractures and joint deformities are frequent complications, which limit the functional abilities of the children from an early age and are a main life-long challenge for social integration and participation. The functional limitations imposed by the combination of weak paretic muscles and contractures in early childhood also reduce the child´s possibilities of active exploration of its environment and social interaction with its peers. This may have secondary impact on cognitive development and cognitive performance later in life.

Therefore, early intervention to prevent contractures is pivotal in helping motor and cognitive development in children with CP and thereby enable social integration and optimal cognitive and motor performance throughout their life time. The importance of prevention of contractures is also emphasized by the realization that none of the surgical, medical or physical therapies that we have available provide an efficient treatment of contractures once they have become manifest and interfere with joint mobility.

There is growing evidence that reduced growth of muscles is a key factor in the development of contractures. If muscles fail to grow at the same rate as bones they will be subjected to abnormal tension. This and the lack of muscle use may stimulate growth of connective tissue in the muscles causing a stiffer extracellular matrix. Growth of the medial gastrocnemius muscle in infants with CP deviates from that of typically developing (TD) infants around the age of 12-15 month. Pathologically increased stiffness of the muscle tissue is seen some months later consistent with a causal relation between reduced growth and increased stiffness. These findings indicate that efficient prevention of contractures will have to take place before the age of one years and will need to focus on stimulation of muscle growth as a key factor.

Muscle growth depends crucially on muscle use, which is the exact challenge that infants with CP are faced with. How do we get a child who has difficulty activating its muscles to do so when that child has no prior experience of using its muscles and limbs and has little verbal understanding of what it is we want it to do? There is now evidence to support that the early development of the motor system is highly plastic and depends crucially on activity-dependent interaction with the environment. Experimental evidence from kittens and rodents support the existence of a sensitive period soon after birth where descending connections from the motor cortex to the spinal cord are re-organized in an activity-dependent manner. Functional deficits in mature animals who have received central motor lesions prior to or in relation to birth appear to depend on the extent to which this activity-dependent re-organization takes place during the sensitive period. It is unknown whether a similar sensitive period exists in humans, but there is reason to believe that the first 5-6 month after birth constitute a period where the motor system undergo rapid changes that may resemble the sensitive period in rodents and kittens. This period is characterized in humans by so-called fidgety movements (FM) which may reflect a ´calibration´ of the sensori-motor system, where descending connections are re-organized similar to what is seen in animals. Children also acquire the ability of goal-directed movements using visual feedback during this period, which may be related to maturation of the connections from motor cortex to the spinal cord. There is also evidence that 5-6 month old children have acquired a sense of agency over their own movements and a basic understanding of how they may use their body to control their environment. Sensory feedback and reward that are associated to successful behavior play an important role in this early establishment of movement control. Thelen & Fissher showed that when infants at an very early age can activate a mobile by own spontaneous movements, movement of the infant increased. The initial 5-6 month after term may therefore provide a window of opportunity where it is possible to facilitate normal development of movement and thereby also prevent contractures through the concomitant muscle growth-stimulus. An intervention in which infants in that age group are stimulated to move by their parents at home under supervision by therapists has indeed been demonstrated to improve motor development in infants with high risk of cerebral palsy. Home-training technology that may facilitate the training and the interaction between therapists and the families are also now becoming available and have shown promising effects on motor development in preterm infants . Intensive goal-oriented training involving experiences of success and frequent reward within the first 5-6 month is therefore central in the intervention that we propose in the present protocol for prevention of contractures in infants at high risk of developing CP.

Muscle growth does not only depend on neural and mechanical stimuli, but also on nutritional and metabolic stimuli. It is therefore important also to consider the nutritional status of the infant and especially whether nutrients that have a specific muscle growth promoting effect are delivered in sufficient quantity to the infant either through breast feeding or breast milk substitutes. The polyunsaturated fatty acid, Docosahexaenic acid (DHA) is considered essential for maturation of the developing brain and may also facilitate muscle growth. Supplementation with DHA is not recommended for healthy term-born infants, but may be important for development of preterm infants and especially for infants with brain lesion. In addition, Vitamin D also plays a role in regulating muscle growth and deficiency of Vitamin D has been suggested to be of importance in neurodevelopmental disorders. It is not clear whether early Vitamin D supplementation has beneficial effects on neurodevelopment and muscle growth, but is recommended for newborns in countries with limited sun exposure because of its beneficial effects on bone metabolism. Information about the nutritional status of mother and infant and subsequent supplementation could therefore be of importance to enhance facilitation of muscle growth in the infants.

It should also be considered whether stimuli that may substitute the neural activation of the muscles such as electrical stimulation may be used when the child is not otherwise active (for instance during sleep) to help maintain muscle growth. Electrical muscle stimulation has been shown to diminish muscle atrophy in adults. The facilitation of muscle growth may help to postpone contracture development until communication with the (older) infant is easier and training goals may therefore be achieved more easily.

The purpose of the present paper is consequently to describe a study protocol for a two-group open-label randomized clinical trial with blinded assessment of an early intervention program directed towards prevention of contractures.

Study Type

Interventional

Enrollment (Anticipated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Denmark
    • København City
      • Charlottenlund, København City, Denmark, 2920
        • Recruiting
        • Elsass Foundation
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 4 months (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Infants younger than 17 weeks CA with suspicion of brain lesion determined from a medical assessment, by MRI or ultrasound scan or abcent fidgety movements (FM) determined as part of General Movement Asessement (GMA) will be included. The brain lesion should be rated severe enough by the clinician to have informed the parents of the associated risk of CP.

Exclusion Criteria:

  • Infants otherwise eligible but with severe genetic abnormalties, severe heart problems, metabolic diseases, or still hospitalized will not be selected for the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Control
Elsass Standard Care
ACTIVE_COMPARATOR: Intervention
Enriched eviroment, Feed back training, Electrical stimulation, nutrition
Behavioral: CONTRACT

The intervention will consist of four elements:

  1. Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)
  2. Home Activity Plan (HAP)
  3. Home-based Feedback training
  4. Electrical muscle stimulation

Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle growth rate
Time Frame: 48 months

The primary outcome measure is the rate of muscle growth in the children evaluated from the start of the study until the final end point measurement at 48 month.

Researchers with high experience in the use of ultrasound (US) examines the entire length of the MG muscle to assess muscle volume. Height, weight, circumference of the widest part of the crus and fibula length is measured. US is performed on the most affected leg or if possible, on both legs, with the infant's ankle fixed in a neutral angle. To estimate muscle thickness and fascicle length one recording is performed with the probe positioned longitudinally at the mid-belly of the MG, with the infant's ankle fixed in a 90-degree angle. The probe was hand-held and fixed vertically with the lower leg for all images.
48 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of passive stiffness and reflex stiffness
Time Frame: 48 months

Passive and reflex-mediated stiffness of the ankle plantar-flexors will be objectively assessed according to the methods described in Lorentzen et al. (Lorentzen et al 2010) and Willerslev-Olsen et al (Willerslev-Olsen et al 2018). Data will be sampled at a rate of 512Hz and transferred to a computer via Bluetooth for further analysis in Matlab (Mathworks, Natick, MA, USA).

With the use of the device the researcher will move the ankle joint from maximal plantar flexed position to maximal dorsiflexion in order for the devise to estimate the ROM. Manual movements will then be performed by the researcher at either a slow velocity (~<20deg/sec) or as fast as possible through the entire ROM. EMG activity is sampled from bipolar surface EMG electrodes (0.5mm diameter, 2cm between electrodes; Ambu Blue Sensor NF-00-S/12; Ambu, Ballerup, Denmark) placed over the soleus muscle at the distal part of the gastrocnemius muscles and the Tibialis Anterior muscle. The device is equipped with strain
48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Copenhagen

Collaborators

Elsass Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 20, 2021

Primary Completion (ANTICIPATED)

December 1, 2025

Study Completion (ANTICIPATED)

December 1, 2029

Study Registration Dates

First Submitted

January 29, 2020

First Submitted That Met QC Criteria

January 29, 2020

First Posted (ACTUAL)

January 31, 2020

Study Record Updates

Last Update Posted (ACTUAL)

November 4, 2022

Last Update Submitted That Met QC Criteria

November 1, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CONTRACT333

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The university of Copenhagen has a data server available for open acces to research data. We aim to make all annonymised data available through the server as soon as the study has been published in a peer reviewed scientific journal.

IPD Sharing Time Frame

When the study has been published in a peer reviewed scientific journal.

IPD Sharing Access Criteria

University affiliation

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy

Clinical Trials on CONTRACT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe